<DOC>
	<DOCNO>NCT01248156</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) prevalent heart rhythm disorder United States , affect 2.5 million individual may cause stroke , palpitation , heart failure , even death . Unfortunately , therapy AF limit . Anti-arrhythmic rate-controlling drug poorly tolerate , frequent side effect reduce stroke risk . Ablation emerge , minimally invasive therapy attract considerable attention may eliminate AF . Unfortunately , AF ablation technically challenging , success 50-70 % ( versus &gt; 90 % arrhythmia ) serious risk . A major cause limitation mechanisms human AF know thus ablation direct . As result , AF ablation empiric result extensive destruction atrium . This project perform research well understand AF determine abnormal activity small region widespread region heart cause AF . By perform study patient clinical procedure , project may lead paradigm shift understand treatment AF .</brief_summary>
	<brief_title>The Maintenance Human Atrial Fibrillation</brief_title>
	<detailed_description>This proposal test hypothesis spatially localize site maintain ongoing human AF , ablation driver may eliminate AF long-term followup . The investigator study atrial fibrillation patient undergoing ablation , identify region may sustain AF , ablate . The study design identify site may maintain AF , use map AF prior ablation . Once identify , site target ablated use traditional method . This process repeat six time . The location site record , compare traditional site AF ablation , include pulmonary vein leave atrial roof . They also study presence complex fractionate electrograms high dominant frequency . Patients persistent , long standing persistent , paroxysmal AF include , patient follow 6-12 month .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Arrhythmias , Cardiac</mesh_term>
	<criteria>INCLUSION CRITERIA STUDY SUBJECTS : patient undergo electrophysiology study ( EPS ) ablation ( ) paroxysmal AF ( nonrheumatic ) whose AF episodes selfterminate &lt; 7 day , ( b ) persistent AF ( nonrheumatic ) whose AF episodes last &gt; or= 7 day terminate DC cardioversion antiarrhythmic drug recur within 24 hour . AF patient must fail &gt; or= 1 antiarrhythmic drug INCLUSION CRITERIA ALL SUBJECTS : full evaluation focus diabetes mellitus , hypertension , coronary disease , leave ventricular ejection fraction ( LVEF ) . We document whether AF relate time vagal activity ( meal sleep ) exercise . We record use drug affect reninaldosteroneangiotensin system ( RAAS ) statins , may protect atrial fibrosis AF . We document serum potassium level , since slight elevation slow CV vitro . We record 12lead ECG echocardiography leave atrial diameter , stress test and/or coronary angiography indicate . event monitor recording daily transmission least one week document AF burden ( study subject ) exclude AF ( control subject ) . must withhold amiodarone &gt; 30 day antiarrhythmic drug &gt; 5 halflives . EXCLUSION CRITERIA FOR ALL SUBJECTS : active coronary ischemia past year , since protocol use isoproterenol rheumatic valve disease , lead distinct AF increase thromboembolic risk prior ablation cardiac surgery , alters atrial electrophysiology LA clot dense contrast TEE derange serum electrolyte , K+ outside 4.05.0 mmol/l leave atrial diameter &gt; 60 mm LVEF &lt; 40 % New York Heart Association heart failure &gt; Class II , exclude distinct , heartfailure relate remodel thrombotic disease , venous filter , transient ischemic attack cerebrovascular accident , minimize additional risk pregnancy , minimize fluoroscopy . As part routine clinical care , female patient childbearing age receive ÃŸHCG pregnancy test . Any test positive include research study inability unwillingness provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>